Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: Putting guidelines into practice

McMurray John, Cohen Solal Alain, Dietz Rainer, Eichhorn Eric, Erhardt Leif, Hobbs Richard, Maggioni Aldo, Ileana L. Pina, Soler Soler Jordi, Swedberg Karl

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Surveys of prescribing in both hospitals and primary care have shown delays in translating improved survival data from clinical trials into clinical practice thereby denying patients the benefits of proven treatments, such as the angiotensin converting enzyme inhibitors. This may be due to unfamiliarity with clinical guidelines and concerns about adverse events. Recent trials have shown that substantial improvements in survival are associated with spironolactone and beta-blocker therapy. In order to accelerate the uptake of these treatments, and to ensure that all eligible patients should receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of heart failure. The objective of these recommendations is to provide practical guidance for non-specialists in order to support the implementation of evidenced-based therapy for heart failure. These practical recommendations are meant to supplement rather than replace existing guidelines.

Original languageEnglish (US)
Pages (from-to)495-502
Number of pages8
JournalEuropean Journal of Heart Failure
Volume3
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Spironolactone
Practice Guidelines
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Guidelines
Survival
Therapeutics
Primary Health Care
Clinical Trials

Keywords

  • Angiotensin converting enzyme inhibitors
  • Beta-blockers
  • Clinical recommendations
  • Heart failure
  • Spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure : Putting guidelines into practice. / John, McMurray; Alain, Cohen Solal; Rainer, Dietz; Eric, Eichhorn; Leif, Erhardt; Richard, Hobbs; Aldo, Maggioni; Pina, Ileana L.; Jordi, Soler Soler; Karl, Swedberg.

In: European Journal of Heart Failure, Vol. 3, No. 4, 2001, p. 495-502.

Research output: Contribution to journalArticle

John, McMurray ; Alain, Cohen Solal ; Rainer, Dietz ; Eric, Eichhorn ; Leif, Erhardt ; Richard, Hobbs ; Aldo, Maggioni ; Pina, Ileana L. ; Jordi, Soler Soler ; Karl, Swedberg. / Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure : Putting guidelines into practice. In: European Journal of Heart Failure. 2001 ; Vol. 3, No. 4. pp. 495-502.
@article{71d82885b3aa4f65a4be0f6f09eef7a3,
title = "Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: Putting guidelines into practice",
abstract = "Surveys of prescribing in both hospitals and primary care have shown delays in translating improved survival data from clinical trials into clinical practice thereby denying patients the benefits of proven treatments, such as the angiotensin converting enzyme inhibitors. This may be due to unfamiliarity with clinical guidelines and concerns about adverse events. Recent trials have shown that substantial improvements in survival are associated with spironolactone and beta-blocker therapy. In order to accelerate the uptake of these treatments, and to ensure that all eligible patients should receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of heart failure. The objective of these recommendations is to provide practical guidance for non-specialists in order to support the implementation of evidenced-based therapy for heart failure. These practical recommendations are meant to supplement rather than replace existing guidelines.",
keywords = "Angiotensin converting enzyme inhibitors, Beta-blockers, Clinical recommendations, Heart failure, Spironolactone",
author = "McMurray John and Alain, {Cohen Solal} and Dietz Rainer and Eichhorn Eric and Erhardt Leif and Hobbs Richard and Maggioni Aldo and Pina, {Ileana L.} and Jordi, {Soler Soler} and Swedberg Karl",
year = "2001",
doi = "10.1016/S1388-9842(01)00173-8",
language = "English (US)",
volume = "3",
pages = "495--502",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure

T2 - Putting guidelines into practice

AU - John, McMurray

AU - Alain, Cohen Solal

AU - Rainer, Dietz

AU - Eric, Eichhorn

AU - Leif, Erhardt

AU - Richard, Hobbs

AU - Aldo, Maggioni

AU - Pina, Ileana L.

AU - Jordi, Soler Soler

AU - Karl, Swedberg

PY - 2001

Y1 - 2001

N2 - Surveys of prescribing in both hospitals and primary care have shown delays in translating improved survival data from clinical trials into clinical practice thereby denying patients the benefits of proven treatments, such as the angiotensin converting enzyme inhibitors. This may be due to unfamiliarity with clinical guidelines and concerns about adverse events. Recent trials have shown that substantial improvements in survival are associated with spironolactone and beta-blocker therapy. In order to accelerate the uptake of these treatments, and to ensure that all eligible patients should receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of heart failure. The objective of these recommendations is to provide practical guidance for non-specialists in order to support the implementation of evidenced-based therapy for heart failure. These practical recommendations are meant to supplement rather than replace existing guidelines.

AB - Surveys of prescribing in both hospitals and primary care have shown delays in translating improved survival data from clinical trials into clinical practice thereby denying patients the benefits of proven treatments, such as the angiotensin converting enzyme inhibitors. This may be due to unfamiliarity with clinical guidelines and concerns about adverse events. Recent trials have shown that substantial improvements in survival are associated with spironolactone and beta-blocker therapy. In order to accelerate the uptake of these treatments, and to ensure that all eligible patients should receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of heart failure. The objective of these recommendations is to provide practical guidance for non-specialists in order to support the implementation of evidenced-based therapy for heart failure. These practical recommendations are meant to supplement rather than replace existing guidelines.

KW - Angiotensin converting enzyme inhibitors

KW - Beta-blockers

KW - Clinical recommendations

KW - Heart failure

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=0034882356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034882356&partnerID=8YFLogxK

U2 - 10.1016/S1388-9842(01)00173-8

DO - 10.1016/S1388-9842(01)00173-8

M3 - Article

C2 - 11511437

AN - SCOPUS:0034882356

VL - 3

SP - 495

EP - 502

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -